Flesinoxan

Flesinoxan

Flesinoxan
Systematic (IUPAC) name
4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Registry Number
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider
UNII  YesY
KEGG
Chemical data
Formula C22H26FN3O4
Molecular mass 415.458 g/mol

Flesinoxan (DU-29,373) is a potent and selective 5-HT1A receptor partial/near-full agonist of the phenylpiperazine class.[1][2][3] Originally developed as a potential antihypertensive drug,[1][2][4] flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests.[5][6] As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability.[7][8] Unfortunately however, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[9]

In patients, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.[8][2]

See also

References

  1. ^ a b
  2. ^ a b c
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^ a b
  9. ^